Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05795101 · ClinicalTrials.gov registry record · Phase 2
TRUDI: TDXD+Durva in HER2+/Low IBC
A Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Filipa Lynce, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT05795101 is a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Filipa Lynce, MD. The registered enrollment target is 63 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05795101, a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Filipa Lynce, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Conditions Studied
Interventions
- DRUG Trastuzumab deruxtecan
- DRUG Durvalumab
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2032-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05795101
The ClinicalTrials.gov registry entry for NCT05795101 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Filipa Lynce, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab deruxtecan is the first listed.
NCT05795101 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT05795101 about?
NCT05795101 is a clinical study titled "TRUDI: TDXD+Durva in HER2+/Low IBC". The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of th...
What is the current status of trial NCT05795101?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2023-05-04. Estimated completion is 2032-12-01.
What conditions does trial NCT05795101 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer, Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2 Low Breast Adenocarcinoma.
What interventions are being tested in trial NCT05795101?
The interventions under investigation include: Trastuzumab deruxtecan (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT05795101?
This trial is sponsored by Filipa Lynce, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05795101 being conducted?
This trial has 3 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.